Literature DB >> 8347929

Polymorphism of the streptokinase gene: implications for the pathogenesis of post-streptococcal glomerulonephritis.

H Malke1.   

Abstract

Recent studies of streptokinase genes from epidemiologically and clinically defined streptococci of groups A, C and G have provided evidence of the polymorphism of the streptokinase locus in the chromosome of pathogenic streptococci. This review considers genetic and pathogenetic data suggesting that there exists a causal relationship between nephritis strain-associated streptokinase production and the initial stages of post-streptococcal glomerulonephritis (PSGN). Currently available sequence information allows to recognize, in the middle of the streptokinase molecule, a major variable region, V1, of about 70 amino acid residues in which sequence identity drops to below 50% when the proteins from nephritogenic and non-nephritogenic strains are compared. The V1 regions, although showing microheterogeneity within either protein category, appear to be more hydrophobic and possess a higher content of ordered secondary structures in the "nephritogenic" molecules. As a working hypothesis, they may be considered the nephrotropic domain(s) with which streptokinases from nephritogenic strains bind to glomerular structures and activate plasminogen in situ, thus triggering the cascade of proteolytic processes leading to PSGN.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8347929     DOI: 10.1016/s0934-8840(11)80842-x

Source DB:  PubMed          Journal:  Zentralbl Bakteriol        ISSN: 0934-8840


  10 in total

1.  Absence of SpeB production in virulent large capsular forms of group A streptococcal strain 64.

Authors:  R Raeder; E Harokopakis; S Hollingshead; M D Boyle
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Structural diversity of streptokinase and activation of human plasminogen.

Authors:  Sergio Lizano; Kenneth H Johnston
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

Review 3.  Streptokinase--the drug of choice for thrombolytic therapy.

Authors:  Adinarayana Kunamneni; Thaer Taleb Abed Abdelghani; Poluri Ellaiah
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

4.  Direct Host Plasminogen Binding to Bacterial Surface M-protein in Pattern D Strains of Streptococcus pyogenes Is Required for Activation by Its Natural Coinherited SK2b Protein.

Authors:  Vishwanatha Chandrahas; Kristofor Glinton; Zhong Liang; Deborah L Donahue; Victoria A Ploplis; Francis J Castellino
Journal:  J Biol Chem       Date:  2015-06-12       Impact factor: 5.157

5.  Cloning, expression, sequence analysis, and characterization of streptokinases secreted by porcine and equine isolates of Streptococcus equisimilis.

Authors:  A R Caballero; R Lottenberg; K H Johnston
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

Review 6.  Pathogenesis of group A streptococcal infections.

Authors:  M W Cunningham
Journal:  Clin Microbiol Rev       Date:  2000-07       Impact factor: 26.132

7.  Molecular characterization of a major serotype M49 group A streptococcal DNase gene (sdaD).

Authors:  A Podbielski; I Zarges; A Flosdorff; J Weber-Heynemann
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

8.  Genetic organization of the streptokinase region of the Streptococcus equisimilis H46A chromosome.

Authors:  U Mechold; K Steiner; S Vettermann; H Malke
Journal:  Mol Gen Genet       Date:  1993-10

9.  Group A Streptococcus virulence factors genes in north India & their association with emm type in pharyngitis.

Authors:  V Dhanda; H Vohra; R Kumar
Journal:  Indian J Med Res       Date:  2011-01       Impact factor: 2.375

10.  Screening, Cloning and Expression of Active Streptokinase from an Iranian Isolate of S.equisimilis Group C in E. coli.

Authors:  Malihe Keramati; Farzin Roohvand; Mohammad Mehdi Aslani; Shohreh Khatami; Mohammadreza Aghasadeghi; Mehdi Sadat; Arash Memarnejadian; Fatemeh Motevalli
Journal:  Iran J Basic Med Sci       Date:  2013-04       Impact factor: 2.699

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.